Month: October 2026

Shared technology and expanded sales capabilities intended to fuel growth across agriculture and defense sectors

ALLEN, TEXAS, Oct. 28, 2026 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (d/b/a EagleNXT) (“EagleNXT” or the “Company”) (NYSE American: UAVS), a provider of full-stack drone, sensor, counter-UAS, and software solutions, today provided an update on the continued buildout of its sales organization. These efforts are designed to accelerate momentum across the Company’s core markets: Agriculture & Commercial, Public Safety, and Defense.

Over the past year, EagleNXT has invested in scaling its team, integrating experienced sales professionals and subject-matter experts across its comprehensive product lines. This initiative is aimed at deepening customer engagement, expanding vital channel partnerships, and securing long-term revenue opportunities for its dual-use technologies.

“Our investment in the sales organization is a cornerstone of our growth strategy,” said Bill Irby, Chief Executive Officer of EagleNXT. “By building a team that combines deep technical expertise with substantial operational experience, we believe we are better positioned to meet the complex needs of our customers in both the commercial and defense sectors. We believe this expanded reach is fostering stronger customer relationships and a growing partner ecosystem.”

EagleNXT’s enhanced sales force brings significant operational, technical, and industry-specific expertise:

• Defense Excellence: The dedicated defense team possesses more than 90 years of combined military experience across multiple service branches. Personnel hold advanced qualifications including Master Army Aviator and Master Jumpmaster, bolstered by individuals with extensive combat deployments worldwide.
• Advanced Remote-Sensing: The dedicated MicaSense sales organization is focused on accelerating the adoption of advanced remote-sensing solutions. This team brings over 40 years of combined market experience to support partners and customers.
• Operational Expertise: In the Public Safety market, the team includes five members holding FAA Part 107 remote-pilot certifications, providing critical operational insights to customer engagements.

The Company’s global sales infrastructure now spans six countries and supports customers in eight languages, supporting a responsive and informed approach as EagleNXT seeks to expand its footprint in key international markets.

This focus on market-driven sales capabilities underpins EagleNXT’s commitment to pursuing market opportunities and creating long-term value for stakeholders.

For more information about the full suite of EagleNXT products and UAS solutions, contact the EagleNXT Sales team.

About EagleNXT
EagleNXT is a leading provider of full-stack drones, advanced sensors, counter-UAS, and intelligent software solutions that deliver critical aerial intelligence for defense, government, and commercial applications worldwide. With more than one million flights conducted globally, EagleNXT’s platforms are trusted across defense, public safety, agriculture, infrastructure, and environmental monitoring applications. The Company’s drone systems have achieved multiple industry firsts, including FAA approvals for Operations Over People (OOP) and Beyond Visual Line of Sight (BVLOS), as well as EASA C2 certification in Europe and inclusion on the U.S. Department of Defense’s Blue UAS list. EagleNXT’s sensors are integrated on more than 150 different drone models and are used in over 100 research publications worldwide, reinforcing its leadership in precision agriculture, surveying, and environmental sustainability initiatives. For more information, visit https://eaglenxt.com or follow EagleNXT on LinkedIn.

Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on EagleNXT’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the Company’s ability to recruit, integrate and retain qualified sales personnel; the effectiveness of the Company’s sales and channel partner strategies; the timing and fulfillment of current and future purchase orders; the conversion of customer opportunities into revenue; demand for the Company’s products in the agriculture, public safety and defense markets; the availability and timing of government and defense funding; risks associated with international operations; and competition in the unmanned systems market. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, see the risk disclosures in the Company’s most recently filed Annual Report on Form 10-K and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC. All such forward-looking statements speak only as of the date they are made, and EagleNXT undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.

Media Contact
Erica Diverio
ericad@seeztoday.com
+1 (908) 229-0724

Investor Relations Contact
Email: UAVS@EagleNXT.com

BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a definitive agreement with a single healthcare-focused, institutional investor for a registered direct offering of an aggregate of 3,000,000 shares of common stock and a concurrent private placement of unregistered warrants to purchase up to 3,000,000 shares common stock (together, the “Offering”). The gross proceeds to the Company from the Offering are expected to be approximately $4.50 million, before deducting placement agent fees and other estimated offering expenses. The warrants will have an exercise price of $1.65, will be exercisable six months following their issuance and will expire five and a half (5.5) years from the issuance date.

The closing of the Offering is expected to occur on or about October 29, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the Offering for working capital purposes and general corporate procedures.

A.G.P./Alliance Global Partners is acting as the sole placement agent for the Offering.

The shares of common stock are being offered and sold pursuant to an effective shelf registration statement on Form S-3 (File No. 333- 279036), which was declared effective by the Securities and Exchange Commission (“SEC”) on August 7, 2024. A prospectus supplement relating to the registered direct offering and the accompanying prospectus will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Additionally, when available, electronic copies of the prospectus supplement and the accompanying prospectus may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.

The private placement of the warrants and the shares of common stock underlying the warrants is being made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act). Accordingly, the securities issued in the concurrent private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the SEC registering the resale of the shares of common stock within 30 days of the closing of the Offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments for inflammation and immunology. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

• CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in Q1, 2027 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.

• XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease. 

To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward Looking Statements

The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including  Ebstrocel™, XPro™ and INKmune™ trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts: 
David Moss 
Chief Executive Officer 
(561) 710-0512 
info@inmunebio.com

Daniel Carlson 
Head of Investor Relations 
(415) 509-4590 
dcarlson@inmunebio.com

• Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTO
• Results demonstrate sustained disease control through extended follow-up among patients who achieved a complete response after treatment with JELMYTO
• No progression to high-grade disease was observed during extended follow-up

PRINCETON, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative therapies that treat urothelial and specialty cancers, today announced publication of final results from the Olympus long-term follow-up study in Therapeutic Advances in Urology, demonstrating the long-term durability of response with JELMYTO® (mitomycin) for pyelocalyceal solution in adult patients with low-grade upper tract urothelial cancer (LG-UTUC).

Among all 41 patients from the Olympus trial who achieved a complete response following primary chemoablation with JELMYTO (n=41), the median duration of response was 47.8 months, with a median follow-up of 28.1 months (95% CI: 13.1, 60.1). Twenty patients entered the long-term follow-up study with a median follow-up of 53.3 months (95% CI: 27.9, 72.8), and in these patients the median duration of response was not estimable (95% CI: 43.5, not estimable) due to the low event rate. As of March 2025, 75% (15/20) of patients in the long-term follow-up study remained event-free, and no progression to high-grade disease was observed.

“These five-year findings further demonstrate the long-term durability of response achieved with JELMYTO in adults with low-grade upper tract urothelial cancer,” said Phillip Pierorazio, MD, Chief of Urology, Penn Presbyterian Medical Center and Professor of Surgery, Hospital of the University of Pennsylvania and lead author of the study. “The sustained disease control observed during extended follow-up provides additional evidence supporting the long-term benefits of JELMYTO.”

Published in Therapeutic Advances in Urology, the five-year follow-up analysis builds upon previously published Olympus findings and provides extended follow-up of patients who achieved a complete response following treatment with JELMYTO. The publication reinforces the durability of response observed among patients who participated in the analysis.

“We are encouraged by the long-term clinical outcomes in patients who achieved a complete response following treatment with JELMYTO,” said Mark Schoenberg, MD, Chief Medical Officer, UroGen. “The publication of these five-year follow-up data supports JELMYTO as a kidney-sparing treatment option, providing patients with durable, long-lasting results. We look forward to pending real-world data regarding use of JELMYTO from the uTRACT Registry.”

About JELMYTO
JELMYTO® (mitomycin) for pyelocalyceal solution is a mitomycin-containing reverse thermal gel containing 4 mg mitomycin per mL gel approved for the treatment of adult patients with LG-UTUC. JELMYTO is a viscous liquid when cooled and becomes a semi-solid gel at body temperature. The drug slowly dissolves over four to six hours after instillation and is removed from the urinary tract by normal urine flow and voiding. It is approved for administration in a retrograde manner via ureteral catheter or antegrade through a nephrostomy tube. The delivery system allows the initial liquid to coat and conform to the upper urinary tract anatomy. The eventual semisolid gel allows for chemoablative therapy to remain in the collecting system for four to six hours without immediately being diluted or washed away by urine flow.

About Upper Tract Urothelial Cancer
Urothelial cancer is the ninth most common cancer globally and the eighth most lethal neoplasm in men in the United States. Between five percent and ten percent of primary urothelial cancers originate in the ureter or renal pelvis and are collectively referred to as UTUC. In the United States, there are approximately 6,000 – 7,000 new or recurrent LG-UTUC patients annually. Most cases are diagnosed in patients over 70 years old, and these older patients often have multiple comorbidities. There are limited treatment options for UTUC, with the most common being endoscopic surgery or nephroureterectomy (removal of the entire kidney and ureter). Treatment with endoscopic surgery can be associated with a high rate of recurrence and relapse.

About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product, JELMYTO (mitomycin) for pyelocalyceal solution, is approved to treat low-grade upper tract urothelial cancer, and our second product is approved for adult patients with recurrent LG-IR-NMIBC. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.

APPROVED USE FOR JELMYTO
JELMYTO® is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC).

IMPORTANT SAFETY INFORMATION

You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.

Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you:

• are pregnant or plan to become pregnant. JELMYTO can harm your unborn baby. You should not become pregnant during treatment with JELMYTO. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO and for 6 months after the last dose. Males being treated with JELMYTO: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO and for 3 months after the last dose.
• are breastfeeding or plan to breastfeed. It is not known if JELMYTO passes into your breast milk. Do not breastfeed during treatment with JELMYTO and for 1 week after the last dose.
• Tell your healthcare provider if you take water pills (diuretic).

How will I receive JELMYTO?

• Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO treatment.
• You will receive your JELMYTO dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO according to your healthcare provider’s instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses.
• JELMYTO is given to your kidney through a tube called a catheter.
• During treatment with JELMYTO, your healthcare provider may tell you to take additional medicines or change how you take your current medicines.

After receiving JELMYTO:

• JELMYTO may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours.
• To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing.

JELMYTO may cause serious side effects, including:

• Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO.
• Bone marrow problems. JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. Your healthcare provider may need to temporarily or permanently stop JELMYTO if you develop bone marrow problems during treatment with JELMYTO.
• The most common side effects of JELMYTO include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please see JELMYTO Full Prescribing Information, including the Patient Information, for additional information.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the implications of the Olympus five-year follow-up study findings, including the potential long-term benefits of JELMYTO in adult patients with LG-UTUC; JELMYTO’s continued positioning as a kidney-sparing treatment option; the anticipated real-world data regarding use of JELMYTO from the uTRACT Registry; and the potential of UroGen’s RTGel platform technology to improve the therapeutic profiles of existing drugs and enable longer exposure of urinary tract tissue to medications. Words such as “may,” “potential,” “will,” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: preliminary clinical results may not be indicative of results that may be observed in the future; potential safety and other complications related to UroGen’s products and product candidates; risks related to our and our licensors’ ability to protect our respective patents and other intellectual property, including the fact that UroGen’s or its licensors’ pending patent applications may not be successful, and in such event, the duration of intellectual property protection would be more limited; the ability to maintain regulatory approval; complications associated with commercialization activities; labeling limitations; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s products and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen’s RTGel technology and UroGen’s products and product candidates may not perform as expected; and the impacts of general macroeconomic and geopolitical conditions on UroGen’s business and financial position. These and other risks and uncertainties are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the U.S. Securities and Exchange Commission on August 5, 2026. In light of these risks and uncertainties, the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
(609) 460-3588 Ext. 1093

MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
(609) 460-3566 Ext. 1083

Targeted for Launch in 2028, Freedom Will Be the First U.S. Nuclear Fission Reactor-Powered Interplanetary Spacecraft

SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading technology company in the defense, national security, and space domains, today announced a $33.6 million contract award to design, build, and deliver the power conversion system for NASA’s Space Reactor-1 Freedom. Kratos will be executing this work as a subcontractor to Sierra Lobo, Inc., under their NASA SpaceDOC III contract. Targeted for launch in 2028, SR-1 Freedom will be the first nuclear fission reactor-powered interplanetary spacecraft, designed to travel beyond Earth’s orbit to Mars, demonstrate advanced nuclear electric propulsion (NEP), and successfully deliver the SkyFall payload.

Space Reactor-1 Freedom will be the first spacecraft ever to demonstrate fission power beyond
Earth’s orbit, traveling to Mars to deliver a sciece payload called SkyFall.
Photo Credit: NASA/Alberto Bertolin

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/12b16ebc-f55f-4605-8092-2eac7e8dfd58

Under this subcontract, Kratos will provide a compact, space-qualified closed Brayton cycle power conversion system. This crucial component serves as the mechanical bridge between SR-1 Freedom’s onboard fission reactor and the spacecraft’s power distribution and electric propulsion subsystems. It converts the thermal energy generated by the reactor into the vital electrical power required to drive SR-1’s propulsion thrusters and sustain all critical spacecraft operations.

Nuclear electric propulsion utilizes a fission-based, nuclear power module to generate electricity, powering highly efficient electric thrusters rather than relying solely on conventional chemical thrusters. By accelerating charged particles to create a gentle but relentless thrust, NEP allows the spacecraft to gradually build immense velocity. Because they can operate continuously for months or years, NEP-equipped spacecraft can reach Mars utilizing significantly less propellant than traditional chemically propelled spacecraft. This unprecedented efficiency drastically reduces fuel requirements, freeing up critical mass for scientific instruments, cargo, and future crew-support equipment.

“Being selected to power SR-1 Freedom is a generational honor for Kratos,” said Stacey Rock, President of Kratos Turbine Technologies Division. “SR-1 is the spacecraft that turns space nuclear propulsion from concept into reality; it is the vehicle that will help answer whether America leads the third space race or watches it from the sidelines. By delivering the power conversion heart of SR-1 Freedom, Kratos is helping NASA give birth to the ‘Nuclear NASA’ that will open the outer solar system, shorten the path to Mars, and strengthen our national security in space.”

NASA has positioned the SR-1 Freedom mission as a cornerstone in a broader space nuclear initiative. The mission aims to launch the first U.S. space reactor since 1965, paving the way for a transformative era of deep space exploration. SR-1 Freedom is strategically structured to mitigate development risks and cultivate the necessary industrial base for future deep-space operations and will facilitate follow-on concepts like Lunar Reactor-1 (LR-1), which is envisioned as a sun-independent power source for NASA’s upcoming Moon Base efforts. The SR-1 Freedom contract adds to Kratos’ expanding portfolio of advanced propulsion, power, and hypersonics work. This milestone reinforces the company’s broader corporate strategy of leveraging strategic internal investments to support critical national security and next-generation space programs.

For more information on Kratos and its advanced space and hypersonic programs, visit www.kratosdefense.com.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

MADRID and CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events:

13th BioCentury–BayHelix China Healthcare Summit, November 2-4
Location: The St. Regis Shanghai Jingan, Shanghai, China.
Presentation date and time: November 3, 3:00-3:15pm local time

Jefferies London Healthcare Conference 2026, November 16-19
Location: The Waldorf Hilton Aldwych, London, United Kingdom.

London Biotechnology Show, November 18-19
Location: ExCeL London, London, United Kingdom.

Oryzon management will be available for one-on-one meetings during the conferences.

About Oryzon
Founded in 2000 and headquartered in Barcelona, Spain, Oryzon (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology. Oryzon’s team comprises highly experienced pharmaceutical professionals based in Barcelona, Boston, and New Jersey. The Company has an advanced clinical portfolio built around two LSD1 inhibitors: iadademstat, its oncology/hematology program, which is being evaluated in several ongoing Phase I and II studies and has demonstrated strong preliminary clinical activity in acute myeloid leukemia, including a 100% overall response rate (ORR) in first-line AML; and vafidemstat, its lead CNS program, which is Phase III–ready in borderline personality disorder (BPD) and is in a Phase IIb study in schizophrenia. In addition, Oryzon is advancing a broader epigenetics pipeline targeting other mechanisms, including HDAC6, for which the Company has nominated ORY-4001 as a clinical candidate for potential development in Charcot–Marie–Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and other neurological disorders. The Company also operates a robust platform for biomarker identification and target validation across malignant and neurological diseases. For more information, visit www.oryzon.com

FORWARD-LOOKING STATEMENTS
This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.

Spain	Oryzon	IR & Media, Europe & US
Patricia Cobo/Mario Cordera	Emili Torrell	Sandya von der Weid
Atrevia	Chief BD Officer	LifeSci Advisors, LLC
+34 91 564 07 25  +34 673 33 97 65	+34 93 515 1313	+41 78 680 05 38
pcobo@atrevia.com  mcordera@atrevia.com	etorrell@oryzon.com	svonderweid@lifesciadvisors.com

Year-over-year revenue growth for the third quarter of 35.9% driven primarily by expanding commercial customer base across healthcare, aerospace and data center markets

Year-to-date book-to-bill of 1.46x reflects strong demand and robust pipeline
across defense and commercial markets

Management increases revenue growth guidance to approximately 40% for 2026, from its prior guidance of 25% to 30%, as a result of stronger than expected third quarter sales and orders

ESCONDIDO, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (“OSS” or the “Company”) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML), autonomy and sensor processing at the edge, reported results for the third quarter ended September 30, 2026. Third quarter and nine-month comparisons are to the same year-ago periods unless otherwise noted. On December 30, 2025, the Company closed a definitive agreement to sell all assets and operations of Bressner Technology GmbH. All operations, assets, and liabilities associated with the sale of Bressner have been classified as discontinued operations.

“Our third quarter results were better than expected and reflect accelerating momentum across our business, supported by growing demand for our Enterprise Class compute solutions and the expanding diversity of our customer base,” stated OSS President and CEO, Mike Knowles. “We are particularly encouraged by the composition of our third quarter revenue growth, which was primarily driven by higher sales to commercial customers across healthcare, commercial aerospace, and specialized data center applications, complementing our established strength and continued momentum in defense markets. Expanding customer diversification, combined with higher average order values, reflects growing demand for our differentiated compute solutions across multiple end markets.”

“Our pipeline remains robust, with a year-to-date book-to-bill ratio of 1.46x reflecting strong underlying demand for our solutions. While third quarter bookings were influenced by the timing of customer orders, we expect several large, multimillion-dollar orders to close during the fourth quarter and continue to advance what we believe to be potentially transformative opportunities across our core defense and commercial markets. We believe these opportunities reflect our strengthening competitive position and provide a solid foundation for sustained growth,” continued Mr. Knowles.

“Third quarter adjusted EBITDA increased 33.7% year-over-year to $0.3 million. In the quarter, we recognized $0.5 million of bad debt expense related to the bankruptcy filing of a former customer and $0.4 million of legal expenses related to a previously disclosed settlement with a former customer. Excluding these two items, third quarter adjusted EBITDA would have been approximately $1.2 million, or nearly 10% of third quarter total revenue, demonstrating the underlying profitability and operating leverage of our business. We are excited about the opportunities ahead in the fourth quarter and as we enter 2027, and remain confident in our ability to drive sustainable, profitable growth and long-term shareholder value,” concluded Mr. Knowles.

2026 Third-Quarter Financial Summary

Total revenue from continuing operations increased to $12.6 million, from $9.3 million in the third quarter of 2025. The 35.9% year-over-year increase in total revenue was driven by revenue generated from new customers in 2026 and from higher production volumes with certain existing customers. Key drivers of the revenue increase included initial deliveries to a new customer developing a network of autonomous energy nodes engineered to power compute payloads, higher production deliveries to a commercial aerospace customer for in-flight entertainment systems, and higher sales to a medical imaging OEM to support a breast cancer screening application.

Gross margin from continuing operations was 42.6% for the three months ended September 30, 2026, compared to 45.6% in the prior year quarter. The year-over-year decrease in gross margin percentage was primarily driven by product mix, partially offset by more favorable manufacturing absorption.

Total operating expenses from continuing operations increased 33.7% to $6.2 million. The $1.6 million year-over-year increase in operating expenses was primarily due to $0.5 million of bad debt expense recognized for a receivable with a former customer that entered bankruptcy, $0.4 million of legal fees associated with a previously disclosed legal settlement with a former customer, and $0.5 million of higher stock-based compensation expense due to a higher grant date fair value of RSUs expensed in the current year period. Total operating expenses were partially offset by lower year-over-year R&D expenses.

The Company reported a loss from continuing operations of $0.6 million, or $0.02 per diluted share for the three months ended September 30, 2026, as compared to a loss from continuing operations of $0.4 million, or $0.02 per share, in the prior year period. The Company reported non-GAAP net income from continuing operations of $0.3 million, or $0.01 per diluted share, compared to non-GAAP net income of $31,000, or $0.00 per share, in the prior year period.

Adjusted EBITDA, from continuing operations, a non-GAAP metric, was $0.3 million for the three months ended September 30, 2026, compared to adjusted EBITDA, from continuing operations, of $0.2 million in the prior year period. Adjusted EBITDA for the third quarter of 2026 included expenses of $0.5 million for a bad debt expense and $0.4 million of legal fees associated with the previously disclosed legal settlement with a former customer. 2026 third quarter adjusted EBITDA excluding these expenses would have been $1.2 million.

Net cash used in continuing operations for the nine months ended September 30, 2026, was $12.4 million, compared to net cash used in continuing operations of $5.9 million in the prior year period. 2026 year-to-date net cash included a $6.25 million legal settlement that occurred in the 2026 second quarter, and a year-to-date increase of $7.8 million in inventories to support expected revenue growth.

As of September 30, 2026, the Company reported cash, cash equivalents, and short-term investments of $18.9 million, and total working capital of $37.9 million, compared to cash, cash equivalents, and short-term investments of $31.2 million, restricted cash of $2.2 million and total working capital of $45.3 million at December 31, 2025.

2026 Nine Month Financial Summary

Total revenue from continuing operations increased to $30.0 million, compared to $20.2 million for the same period last year. The 48.3% year-over-year increase in total revenue was driven by revenue generated from new customers in 2026 and from higher production volume with certain existing customers. Key drivers of the revenue increase included higher sales to support the P-8A Poseidon reconnaissance aircraft, higher sales to a medical imaging OEM to support a breast cancer screening application, higher sales for military applications onboard naval vessels and aircraft, initial deliveries to a new customer developing a network of autonomous energy nodes, and higher revenue from customer-funded development programs.

Gross margin from continuing operations was 43.9%, as compared to 44.4% in the prior year. The slight year-over-year decrease in gross margin percentage was primarily driven by product mix, partially offset by more favorable manufacturing absorption and higher engineering efficiencies on customer funded development programs.

Total operating expenses increased 56.5% to $22.4 million, from $14.3 million for the same period last year. The $8.0 million year-over-year increase in operating expenses included a $6.25 million charge related to the legal settlement in the second quarter, as well as a $0.5 million of bad debt expense, primarily driven by provision for a receivable with a former customer that entered bankruptcy, $0.7 million of legal fees associated with a previously disclosed legal settlement with a former customer, and $0.9 million of higher stock-based compensation expense due to a higher grant date fair value of RSUs expensed in the current year period. Total operating expenses were partially offset by lower year-over-year R&D expenses.

OSS reported a loss from continuing operations of $8.3 million, or $0.33 per share, as compared to a loss from continuing operations of $5.1 million, or $0.24 per share, in the prior year. The Company reported non-GAAP net income from continuing operations of $0.4 million, or $0.02 per share, compared to a non-GAAP net loss from continuing operations of $3.7 million, or $0.17 per share in the prior year.

Adjusted EBITDA income, from continuing operations, a non-GAAP metric, was $0.1 million, compared to an adjusted EBITDA loss, from continuing operations, of $3.2 million in the prior year period. Adjusted EBITDA for the first nine-months of 2026 included $0.5 million for a bad debt expense associated with the bankruptcy of a former customer and $0.7 million of legal fees associated with the previously-disclosed legal settlement with a former customer. 2026 year-to-date adjusted EBITDA excluding these expenses would have been $1.4 million.

Income from Discontinued Operations, net of Income Taxes

Income from discontinued operations consists of income from the Company’s Bressner Technologies subsidiary, which was sold on December 30, 2025. Income from discontinued operations also includes the gain recognized on the sale.

The Company recorded no income or loss from discontinued operations, net of income taxes, for the three months ended September 30, 2026, compared to income of $0.6 million in the prior year. For the nine months ended September 30, 2026, loss from discontinued operations, net of income taxes, was $0.2 million, compared to income from discontinued operations, net of income taxes, of $1.4 million in the prior year. The loss in the current year period was due to post-transaction adjustments to the gain on sale of the Bressner business for final net working capital balances.

2026 Full Year Outlook

The Company is executing a strategic plan targeting both commercial and defense markets, aiming to provide integrated solutions and establish OSS as a platform incumbent on large, multi-year programs. This approach is expected to drive long-term value by increasing predictable, recurring revenue and building a strong, multi-year backlog.

Based on its current performance and business outlook, OSS is increasing its full-year 2026 revenue growth guidance. We believe that the Company’s expectations for 2026 reflect better than expected growth across its core defense and commercial markets and expected higher customer-funded development revenue compared with 2025. The Company also continues to monitor potential supply chain constraints affecting certain components, including memory, and the current outlook for the federal government budget. Changes in these assumptions could positively or negatively affect OSS’s 2026 results.

For the full year of 2026, OSS expects:

• Revenue growth of approximately 40%, compared to prior guidance of 25% to 30%
• Gross margin of approximately 40%-42%
• Adjusted EBITDA of $0.5 million to $1.0 million

Conference Call

OSS will hold a conference call to discuss its results for the third quarter of 2026, followed by a question-and-answer period.

Date: Wednesday, October 28, 2026
Time: 10:00 a.m. ET (7:00 a.m. PT)
Toll-free dial-in: 1-800-717-1738
International dial-in: 1-646-307-1865
Conference ID: 32264 (required for entry)
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1773205&tp_key=3a8ee0805b

A replay of the call will be available after 1:00 p.m. ET on October 28, 2026, through November 11, 2026.

Toll-free replay: 1-844-512-2921
International replay: 1-412-317-6671
Passcode: 1132264

About One Stop Systems

One Stop Systems, Inc. (Nasdaq: OSS) is a leader in AI enabled solutions for the demanding ‘edge.’ OSS designs and manufactures Enterprise Class compute and storage products that enable rugged AI, sensor fusion and autonomous capabilities without compromise. These hardware and software platforms bring the latest data center performance to harsh and challenging applications, whether they are on land, sea or in the air.

OSS products include ruggedized servers, compute accelerators, flash storage arrays, and storage acceleration software. These specialized compact products are used across multiple industries and applications, including autonomous trucking and farming, as well as aircraft, drones, ships and vehicles within the defense industry.

OSS solutions address the entire AI workflow, from high-speed data acquisition to deep learning, training and large-scale inference, and have delivered many industry firsts for industrial OEM and government customers.

As one of the fastest growing segments of the multi-billion-dollar edge computing market, AI enabled solutions require—and OSS delivers—the highest level of performance in the most challenging environments without compromise.

OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com. You can also follow OSS on X, YouTube, and LinkedIn.

Non-GAAP Financial Measures

We believe that the use of adjusted earnings before interest, taxes, depreciation and amortization, or adjusted EBITDA, is helpful for an investor to assess the performance of the Company. The Company defines adjusted EBITDA as income (loss) before interest, taxes, depreciation, amortization, acquisition expense, impairment of long-lived assets, financing costs, government funded programs, fair value adjustments from purchase accounting, stock-based compensation expense, and expenses related to discontinued operations. Adjusted EBITDA also excludes the impact of the legal settlement agreement.

Adjusted EBITDA is not a measurement of financial performance under generally accepted accounting principles in the United States, or GAAP. Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash operating expenses, we believe that providing a non-GAAP financial measure that excludes non-cash and non-recurring expenses allows for meaningful comparisons between our core business operating results and those of other companies, as well as providing us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.

Our adjusted EBITDA measure may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial results differently, particularly related to non-recurring and unusual items. Our adjusted EBITDA is not a measurement of financial performance under GAAP and should not be considered as an alternative to operating income or as an indication of operating performance or any other measure of performance derived in accordance with GAAP. We do not consider adjusted EBITDA to be a substitute for, or superior to, the information provided by GAAP financial results.

EBITDA from Continuing Operations
	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
	2026				2025				2026				2025
Loss from continuing operations	$	(593,734	)		$	(380,719	)		$	(8,275,982	)		$	(5,134,263	)
Legal settlement	$	–			$	–				6,250,000				–
Depreciation	$	183,195			$	192,841				549,811				583,278
Amortization of right-of-use assets net of change in operating lease liability	$	(6,223	)		$	(2,595	)			(16,376	)			(6,660	)
Stock-based compensation expense	$	909,622			$	411,687				2,425,963				1,473,442
Interest expense	$	–			$	2,424				–				2,424
Interest income	$	(242,570	)		$	(36,433	)			(853,398	)			(159,795	)
Adjusted EBITDA	$	250,290			$	187,205			$	80,018			$	(3,241,573	)
EBITDA from Discontinued Operations	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
	2026				2025				2026				2025
Income (loss) from discontinued operations, net of income taxes	$	–			$	644,206			$	(157,274	)		$	1,359,387
Post-closing adjustments to gain on sale	$	–			$	–				157,274				–
Depreciation	$	–			$	32,927				–				93,499
Amortization of right-of-use assets net of change in operating lease liability	$	–			$	(113	)							53,796
Stock-based compensation expense	$	–			$	32,934				–				99,514
Interest expense	$	–			$	12,641				–				40,517
Interest income	$	–			$	–				–				555
Provision for income taxes	$	–			$	266,881				–				600,535
Adjusted EBITDA	$	–			$	989,476			$	–			$	2,247,802
Consolidated EBITDA	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
	2026				2025				2026				2025
Net (loss) income	$	(593,734	)		$	263,488			$	(8,433,256	)		$	(3,774,876	)
Legal settlement	$	–			$	–				6,250,000				–
Post-closing adjustments to gain on sale	$	–			$	–				157,274				–
Depreciation	$	183,195			$	225,768				549,811				676,777
Amortization of right-of-use assets net of change in operating lease liability	$	(6,223	)		$	(2,708	)			(16,376	)			47,136
Stock-based compensation expense	$	909,622			$	444,621				2,425,963				1,572,956
Interest expense	$	–			$	15,065				–				42,941
Interest income	$	(242,570	)		$	(36,433	)			(853,398	)			(159,240	)
Provision for income taxes	$	–			$	266,881				–				600,535
Adjusted EBITDA	$	250,290			$	1,176,682			$	80,018			$	(993,771	)

(Dollars may not calculate due to rounding)

Adjusted EPS excludes the impact of certain items and, therefore, has not been calculated in accordance with GAAP. We believe that exclusion of certain selected items assists in providing a more complete understanding of our underlying results and trends and allows for comparability with our peer company index and industry. We use this measure along with the corresponding GAAP financial measures to manage our business and to evaluate our performance compared to prior periods and the marketplace. The Company defines non-GAAP income (loss) as income or (loss) before amortization, government funded programs, impairment of long lived assets, stock-based compensation, expenses related to discontinued operations, and acquisition costs. Non-GAAP income (loss) also excludes the impact of the legal settlement agreement. Adjusted EPS expresses adjusted income (loss) on a per share basis using weighted average diluted shares outstanding.

Adjusted EPS is a non-GAAP financial measure and should not be considered in isolation or as a substitute for financial information provided in accordance with GAAP. These non-GAAP financial measures may not be computed in the same manner as similarly titled measures used by other companies. We expect to continue to incur expenses similar to the adjusted income from continuing operations and adjusted EPS financial adjustments described above, and investors should not infer from our presentation of these non-GAAP financial measures that these costs are unusual, infrequent or non-recurring.

The following table reconciles non-GAAP net income and basic and diluted earnings per share:

Non- GAAP Adjusted EPS from Continuing Operations
	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
	2026				2025				2026				2025
Loss from continuing operations	$	(593,734	)		$	(380,719	)		$	(8,275,982	)		$	(5,134,263	)
Legal settlement		–				–				6,250,000				–
Stock-based compensation expense		909,622				411,687				2,425,963				1,473,442
Non-GAAP net income (loss) from continuing operations	$	315,888			$	30,968			$	399,981			$	(3,660,821	)
Non-GAAP net income (loss) from continuing operations per share:
Basic	$	0.01			$	0.00			$	0.02			$	(0.17	)
Diluted	$	0.01			$	0.00			$	0.02			$	(0.17	)
Weighted average common shares outstanding:
Basic		24,993,832				21,952,963				24,839,830				21,675,802
Diluted		25,899,044				22,840,761				25,933,329				21,675,802
Non- GAAP Adjusted EPS from Discontinued Operations
	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
	2026				2025				2026				2025
Income (loss) from discontinued operations, net of income taxes	$	–			$	644,206			$	(157,274	)		$	1,359,387
Post-closing adjustments to gain on sale		–				–				157,274				–
Stock-based compensation expense		–				32,934				–				99,514
Non-GAAP net income from discontinued operations	$	–			$	677,140			$	–			$	1,458,901
Non-GAAP net income from discontinued operations per share:
Basic	$	–			$	0.03			$	–			$	0.07
Diluted	$	–			$	0.03			$	–			$	0.07
Weighted average common shares outstanding:
Basic		24,993,832				21,952,963				24,839,830				21,675,802
Diluted		25,899,044				22,840,761				25,933,329				22,308,957
Consolidated Non-GAAP Adjusted EPS
	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
	2026				2025				2026				2025
Net (loss) income	$	(593,734	)		$	263,488			$	(8,433,256	)		$	(3,774,876	)
Legal settlement		–				–				6,250,000				–
Post-closing adjustments to gain on sale		–				–				157,274				–
Stock-based compensation expense		909,622				444,621				2,425,963				1,572,956
Non-GAAP net income (loss)	$	315,888			$	708,109			$	399,981			$	(2,201,920	)
Non-GAAP net income (loss) per share:
Basic	$	0.01			$	0.03			$	0.02			$	(0.10	)
Diluted	$	0.01			$	0.03			$	0.02			$	(0.10	)
Weighted average common shares outstanding:
Basic		24,993,832				21,952,963				24,839,830				21,675,802
Diluted		25,899,044				22,840,761				25,933,329				21,675,802

(Dollars may not calculate due to rounding)

Forward-Looking Statements

One Stop Systems cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. Words such as, but not limited to, “anticipate,” “aim,” “believe,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “strategy,” “target,” “will,” “would,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to statements regarding the Company’s anticipated financial performance and outlook for 2026, including expected revenue growth, gross margin and adjusted EBITDA; anticipated customer orders and the timing and likelihood of converting sales opportunities into bookings and revenue; expected demand for the Company’s products across defense and commercial markets; anticipated customer-funded development activity; the Company’s ability to expand its customer base and market opportunities; and its ability to execute its strategic plan, secure positions on large, multi-year programs and achieve sustainable growth and profitability.

The inclusion of forward-looking statements should not be regarded as a representation by One Stop Systems or its partners that any of its plans or expectations will be achieved, including but not limited to expected increases in sales, revenues and profitability, non-GAAP financial measures, our multi-year strategy, expected market growth, continued or new demand for our products, increase in margins, and operating expenses. These statements are based on the Company’s current beliefs and expectations. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in our business, including risks described in our prior press releases and in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our latest Annual Report on Form 10-K and any subsequent filings with the SEC, as well as those relating to current geopolitical conditions, defense spending changes, the Company’s ability to successfully scale production, manage program execution, and meet customer delivery schedules, semiconductor supply constraints, and customer concentration. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Media Contacts:
Robert Kalebaugh
One Stop Systems, Inc.
Tel (858) 518-6154
Email contact

Investor Relations:
Andrew Berger
Managing Director
SM Berger & Company, Inc.
Tel (216) 464-6400
Email contact

ONE STOP SYSTEMS, INC. (OSS) CONSOLIDATED BALANCE SHEETS
	Unaudited				Audited
	September 30,				December 31,
	2026				2025
ASSETS
Current assets
Cash and cash equivalents	$	5,637,841			$	31,174,880
Restricted cash		–				2,200,096
Short-term investments		13,246,688				–
Accounts receivable, net		12,743,025				11,549,718
Inventories, net		13,724,606				5,420,439
Prepaid expenses and other current assets		567,705				472,884
Total current assets		45,919,865				50,818,017
Property and equipment, net		292,229				674,654
Operating lease right-of-use assets		1,086,582				1,216,871
Deposits and other		36,555				38,093
Intangible assets, net		85,695				73,908
Total assets	$	47,420,926			$	52,821,543
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	2,114,154			$	1,716,389
Accrued expenses and other current liabilities		5,679,614				3,630,130
Current portion of operating lease liabilities		267,693				219,097
Total current liabilities		8,061,461				5,565,616
Operating lease liabilities, net of current portion		1,054,602				1,249,862
Total liabilities		9,116,063				6,815,478
Commitments and contingencies
Stockholders’ equity
Common stock, $0.0001 par value; 50,000,000 shares authorized; 25,037,445 and 24,583,775 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively		2,505				2,458
Additional paid-in capital		63,751,064				62,968,973
Accumulated other comprehensive loss		(50,084	)			–
Accumulated deficit		(25,398,622	)			(16,965,367	)
Total stockholders’ equity		38,304,863				46,006,064
Total liabilities and stockholders’ equity	$	47,420,926			$	52,821,543

ONE STOP SYSTEMS, INC. (OSS) UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars may not calculate due to rounding)
	For the Three Months Ended September 30,								For the Nine Months Ended September 30,
	2026				2025				2026				2025
Revenue:
Product	$	12,353,277			$	8,966,978			$	27,822,538			$	19,139,122
Customer funded development		230,241				295,539				2,179,141				1,090,916
		12,583,518				9,262,517				30,001,679				20,230,038
Cost of revenue:
Product		7,135,004				4,944,908				15,765,085				10,560,688
Customer funded development		90,355				95,919				1,059,839				696,579
		7,225,359				5,040,827				16,824,924				11,257,267
Gross profit		5,358,159				4,221,690				13,176,755				8,972,771
Operating expenses:
General and administrative		3,190,639				1,728,012				8,089,248				5,543,820
Legal settlement		–				–				6,250,000				–
Marketing and selling		1,892,397				1,632,506				5,235,314				4,898,135
Research and development		1,109,833				1,271,637				2,779,972				3,838,849
Total operating expenses		6,192,869				4,632,155				22,354,534				14,280,804
Loss from operations		(834,710	)			(410,465	)			(9,177,779	)			(5,308,034	)
Other income (expense), net:
Interest income		242,570				36,433				853,398				159,795
Interest expense		–				(2,424	)			–				(2,424	)
Other (expense) income, net		(1,594	)			(4,263	)			48,399				16,400
Total other income, net		240,976				29,746				901,797				173,771
Loss before income taxes		(593,734	)			(380,719	)			(8,275,982	)			(5,134,263	)
Provision for income taxes		–				–				–				–
Loss from continuing operations		(593,734	)			(380,719	)			(8,275,982	)			(5,134,263	)
Income (loss) from discontinued operations, net of income taxes		–				644,206				(157,274	)			1,359,387
Net (loss) income		(593,734	)			263,487				(8,433,256	)			(3,774,876	)
Per share basis:
Basic:
Continuing operations	$	(0.02	)		$	(0.02	)		$	(0.33	)		$	(0.24	)
Discontinued operations	$	–			$	0.03			$	(0.01	)		$	0.06
Basic (loss) income per share	$	(0.02	)		$	0.01			$	(0.34	)		$	(0.17	)
Diluted:
Continuing operations	$	(0.02	)		$	(0.02	)		$	(0.33	)		$	(0.24	)
Discontinued operations	$	–			$	0.03			$	(0.01	)		$	0.06
Diluted (loss) income per share	$	(0.02	)		$	0.01			$	(0.34	)		$	(0.17	)
Weighted average common shares outstanding:
Basic		24,993,832				21,952,963				24,839,830				21,675,802
Diluted		24,993,832				22,840,761				24,839,830				22,308,957

ONE STOP SYSTEMS, INC. (OSS) UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
	For the Nine Months Ended September 30,
	2026				2025
Cash flows from continuing operating activities:
Loss from continuing operations	$	(8,275,982	)		$	(5,134,263	)
Adjustments to reconcile loss from continuing operations to net cash (used in) continuing operating activities:
Depreciation		549,811				583,278
Provision for (recovery from) credit losses		573,596				(100	)
Amortization of right-of-use assets		130,289				169,723
Stock-based compensation expense		2,425,963				1,473,442
Change in warranty reserves		20,000				30,000
Change in inventory reserves		(548,999	)			(632,783	)
Loss on disposal of property and equipment		11,698
Changes in operating assets and liabilities:
Accounts receivable		(1,766,903	)			(2,696,476	)
Inventories		(7,755,167	)			671,968
Prepaid expenses and other current assets		(96,301	)			(135,855	)
Security deposits		3,019				–
Accounts payable		397,765				1,060,189
Accrued expenses and other current liabilities		2,029,484				(1,152,416	)
Operating lease liabilities		(146,665	)			(176,383	)
Net cash used in continuing operating activities		(12,448,392	)			(5,939,676	)
Cash flows from continuing investing activities:
Purchases of property and equipment		(190,872	)			(108,630	)
(Purchase) sale of marketable securities		(13,296,773	)			3,212,492
Net cash (used in) provided by continuing investing activities		(13,487,645	)			3,103,862
Cash flows from continuing financing activities:
Proceeds from exercise of stock options		206,122				1,022,988
Payment of withholding taxes on stock-based awards		(1,849,946	)			(509,977	)
Proceeds from bank lines of credit		–				1,000,000
Net cash (used in) provided by continuing financing activities		(1,643,824	)			1,513,011
Net change in cash, cash equivalents, and restricted cash from continuing operations		(27,579,861	)			(1,322,803	)
Net cash flow from discontinued operating activities		(157,274	)			1,014,062
Net cash flow from discontinued investing activities		–				(359,249	)
Net cash flow from discontinued financing activities		–				–
Net change in cash, cash equivalents, and restricted cash from discontinued operations		(157,274	)			654,812
Effect of exchange rate changes on cash		–				381,918
Net change in cash, cash equivalents, and restricted cash		(27,737,135	)			(286,073	)
Cash, cash equivalents, and restricted cash, beginning of period:		33,374,976				6,794,093
Cash, cash equivalents, and restricted cash, end of period	$	5,637,841			$	6,508,020

BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it will host a virtual investor event on Tuesday, November 3, 2026 at 11:00 AM ET regarding the ARCHER II Phase 3 program. To register, click here.

Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026. The Company will also highlight the recent strengthening of its Ophthalmology team.

The event will feature Roger Goldberg, MD, MBA (Bay Area Retina Associates and ARCHER II Clinical Investigator), who will join company management to discuss the unmet need and current treatment landscape for geographic atrophy (GA), the advanced form of dry, age-related macular degeneration (AMD) of the retina.

A live question and answer session will follow the formal presentations.

About Roger A. Goldberg, MD, MBA
Roger A. Goldberg, MD, MBA, a native of Boston, graduated from both college and medical school at Yale University. He completed his residency in Miami at the Bascom Palmer Eye Institute, the nation’s top eye hospital and residency-training program. He returned to Boston for a fellowship in Vitreoretinal Diseases and Surgery at Tufts and Ophthalmic Consultants of Boston. Dr. Goldberg is board certified by the American Board of Ophthalmology and is an active member of the American Society of Retinal Specialists, the Retina Society, and the American Academy of Ophthalmology. Dr. Goldberg has published numerous research manuscripts and book chapters, including first-author publications in The New England Journal of Medicine, Ophthalmology, JAMA Ophthalmology, and American Journal of Ophthalmology. His surgical interests include macular surgery, complex retinal detachment repair and complications of cataract surgery.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

Media Contact:
Christian Vaughn
annexonpr@syneoshealth.com

NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) — Satellogic Inc. (NASDAQ: SATL), the infrastructure company for Persistent Global Intelligence (PGI), will hold a conference call on Tuesday, November 10, 2026, at 4:30 p.m. Eastern time to discuss its results for the third quarter 2026 ended September 30, 2026, and will be providing updates on recent commercial advancements, partnerships, and other initiatives and milestones.

Satellogic’s Chief Executive Officer Emiliano Kargieman and Interim Chief Financial Officer Dustin Greer will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed following the call via the investor relations section of the Company’s website here.

To access the call, please use the following information:

Date:	Tuesday, November 10, 2026
Time:	4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-in:	1-877-407-0752
International Dial-in:	1-201-389-0912
Conference Code:	13763257
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1779304&tp_key=7ad56fbb10

A telephone replay will be available approximately three hours after the call and will run through November 24, 2026, by dialing 1-844-512-2921 from the U.S. and Canada, or 1-412-317-6671 from international locations, and entering replay pin number: 13763257. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company’s investor relations section here.

About Satellogic

Founded in 2010, Satellogic (NASDAQ: SATL) builds the infrastructure for Persistent Global Intelligence (PGI): continuous, proactive awareness of the places, assets, and activities that matter. The company combines high-cadence satellite collection, best-in-class technology, AI-accelerated workflows, and sovereign-trusted architecture to help customers move from episodic imagery to persistent monitoring programs.

Satellogic serves allied defense and intelligence agencies, civil governments, and commercial markets that need reliable, scalable awareness of change across large portfolios of sites. Customers can begin with discovery, expand into persistent monitoring, and build toward dedicated or sovereign-controlled capacity as their mission requirements grow. To learn more, please visit: https://www.satellogic.com.

Contacts

Satellogic Investor Relations:
ir@satellogic.com

Satellogic Media Relations:
pr@satellogic.com

Submission backed by clinical data from two clinical studies representing 168 subjects demonstrating quality of life improvements and an approximately 40% reduction in neuropathic pain scores in the active treatment group

ROCKAWAY, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), (“electroCore” or the “Company”), a bioelectronic technology company, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance for its Quell® wearable neuromodulation platform (“Quell”) for the treatment of chronic chemotherapy-induced peripheral neuropathy (CIPN).

CIPN is a common and potentially persistent complication of certain neurotoxic cancer therapies that can significantly affect pain, sensation, physical function, and quality of life. There are currently no drugs or devices approved or cleared by the FDA with an indication specific to CIPN. Current management relies on therapies approved or cleared for other conditions, including off-label treatments. If cleared, Quell would be [among] the first FDA-cleared device[s] with a labeled indication specifically for chronic CIPN.

The 510(k) submission is supported by clinical evidence from two studies involving a total of 168 subjects, including a 142-subject randomized controlled trial and a 26-subject open-label study. Across the studies, treatment with Quell was associated with improvements in CIPN-related symptoms and quality-of-life measures. In the active treatment group, neuropathic pain scores decreased by approximately 40%, compared with approximately 24-33% in the sham group. In an analysis that was not pre-specified of subjects with moderate to severe pain at baseline, neuropathic pain scores decreased by approximately 50% in the active group compared with approximately 30% in the sham group.

The EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Chemotherapy-Induced Peripheral Neuropathy 20-item scale) is a validated patient-reported outcome measure used to assess the severity of peripheral neuropathy symptoms in cancer patients receiving neurotoxic chemotherapy. In the 142-subject randomized controlled trial, subjects treated with Quell demonstrated an 11.6% improvement in EORTC-CIPN20 scores compared with an 8.7% improvement in the sham control group. The between-group difference met the study’s pre-specified statistical significance threshold of 0.2, which was selected because the proof-of-concept study was designed to evaluate preliminary efficacy. In the 26-subject single-site, open-label feasibility study, the 22 subjects who completed the six-week treatment period demonstrated a 13% improvement in EORTC-CIPN20 scores. Across the clinical program, Quell-related adverse events were generally infrequent, mild and self-limiting.

“Chemotherapy-induced peripheral neuropathy can persist long after cancer treatment has ended and can have a profound impact on patients’ daily lives,” said Peter S. Staats, M.D., MBA, Chief Medical Officer of electroCore. “The clinical evidence supporting this submission is particularly encouraging because it includes data from a randomized controlled trial shows encouraging improvements in symptoms that matter to patients, including neuropathic pain and quality of life. Following our interactions with the FDA, we have determined to pursue the 510(k) pathway for this indication. Submitting our 510(k) is an important step toward potentially bringing patients and clinicians a non-pharmacologic treatment option for this difficult-to-treat condition, and we look forward to continuing to work closely with the Agency during its review.”

The submission builds upon clinical data generated with the Quell platform and represents an opportunity for electroCore to expand its neuromodulation portfolio into oncology supportive care. Because the studies supporting the submission have already been completed, the Company has been able to advance the program to this regulatory milestone while leveraging its existing technology platform, clinical evidence, and organizational infrastructure.

A 510(k) premarket notification is intended to demonstrate that a device is substantially equivalent to a legally marketed predicate device. FDA review of the submission will determine whether Quell is substantially equivalent to a legally marketed predicate device for the proposed indication. Submission of a 510(k) does not guarantee that FDA will clear the device, and FDA may request additional information during its review.

About Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy is a frequent adverse effect of several commonly used cancer therapies and may include pain, numbness, tingling, sensory abnormalities, and impaired function. For some patients, symptoms persist for months or years after completion of chemotherapy and can substantially affect quality of life. Despite its clinical burden, treatment options remain limited. There are currently no therapies approved or cleared by the FDA with a labeled indication specifically for CIPN, and patients are commonly treated with therapies approved or cleared for other conditions.

About Quell®

Quell is a wearable neuromodulation platform designed to deliver non-invasive neurostimulation for the treatment of chronic neurological symptoms. The platform is designed for convenient use outside the clinical setting and builds upon electroCore’s broader expertise in bioelectronic medicine and non-invasive neuromodulation. Quell is not cleared by the FDA for the treatment of CIPN.

About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the FDA’s review of the Company’s 510(k) premarket notification for Quell for the treatment of CIPN, the timing and outcome of that review, and the anticipated commercialization of Quell for CIPN, the Company’s future business strategies, growth opportunities, prospects, product development, and market expansion, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the preliminary nature of the clinical evidence, which was generated using a proof-of-concept study design, the possibility that the FDA may determine that Quell is not substantially equivalent to a predicate device, which could require the Company to pursue a De Novo classification request or other regulatory pathway, or may clear Quell for a narrower indication than requested, the possibility that the FDA may request additional clinical data or information, which could delay or prevent clearance, the ability to use strategic partnerships to provide more accessibility to those looking to purchase our consumer devices, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize its products, electroCore’s results of operations and financial performance, inflation and currency fluctuations, and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates, competition from existing therapies, including drugs and devices approved or cleared for other indications that are used to manage CIPN symptoms, which physicians and payors may continue to prefer, and which may limit market acceptance of, or reimbursement for, Quell for CIPN if cleared, and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.

Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com

SAN CLEMENTE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) — Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the following investor conferences:

Stifel 2026 Healthcare Conference
Presentation Format: Corporate overview
Presentation Date: Tuesday, November 10, 2026
Presentation Time: 4:40 p.m. ET
Webcast: Click Here

Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Presentation Format: Corporate overview
Presentation Date: Wednesday, November 11, 2026
Presentation Time: 12:30 p.m. ET
Webcast: Click Here

About Sofwave Medical Ltd.
Sofwave Medical Ltd. (TASE: SOFW) is a global regenerative aesthetics company advancing non-invasive technologies for skin and body. Its proprietary SUPERB™ (Synchronous Ultrasound Parallel Beam) technology delivers controlled ultrasound energy to the mid-dermis to stimulate the body’s natural regenerative response and is FDA-cleared for the treatment of facial lines and wrinkles, lifting the eyebrow and lax submental and neck tissue, improving the appearance of skin laxity on the upper arms, short-term improvement in the appearance of cellulite, and treatment of acne scars.

Sofwave’s portfolio also includes Pure Impact™, which utilizes electrical muscle stimulation (EMS) technology for muscle strengthening, toning and firming. Together, Sofwave’s technologies provide physicians with clinically supported, non-invasive solutions for the evolving needs of aesthetic patients worldwide.

Investor Contact:
Brian Ritchie
LifeSci Advisors LLC
(212) 915-2578
britchie@lifesciadvisors.com